Medical Technology

@xconomy.com 3 years ago

Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More

@xconomy.com 3 years ago

Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally

@xconomy.com 4 years ago

Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More

@xconomy.com 4 years ago

With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14

@xconomy.com 4 years ago

Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

@xconomy.com 4 years ago

Five Years After Y Combinator First Admits Biotechs, They’re Dug In

@xconomy.com 4 years ago

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

@xconomy.com 4 years ago

Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More

@xconomy.com 4 years ago

Review: Inside the House of Lies at Theranos

@xconomy.com 5 years ago

Censinet Takes Off With $7.8M to Track Cyber Risks in Healthcare

@xconomy.com 5 years ago

Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More

@xconomy.com 5 years ago

Six Life Science Firms Close Q3 with an IPO, More Are on the Way

@xconomy.com 5 years ago

In Boston’s Shadow, Rhode Island Fights for Life Science Jobs, Respect

@xconomy.com 5 years ago

Boston Scientific Continues M&A Streak with $202M Deal for Cryterion